Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Source abstract
Abstract
The tumor microenvironmental immune cells (TMICs) consists of myeloid cells (tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, etc.) and lymphocytes (T cells and B cells), all of which could be immunologically suppressed through their interactions with cancer cells. Immunological understanding of the tumor microenvironment (TME) has led to great success in the development of clinical cancer immunotherapeutic. The most advanced cancer immunotherapies are chimeric antigen receptor-modified T cells (CAR-T cells) and checkpoint inhibiting antibodies blocking CTLA4, PD-1 and PD-L1. However, many hurdles remain that should be addressed for improved therapeutic efficacy and reduced side effects such as cytokine release syndrome and patient-death. In recent decades, nanoparticles have been demonstrated as an efficient drug delivery tool due to their ease of modification, biocompatibility and intrinsic tumor targeting effect, and also been applied for cancer immunotherapy. In this review, we briefly introduce the immunosuppressive functions of TMICs and review recent advances in the development of TMIC-targeted nanotherapeutics for cancer immunotherapy. Tumor-associated macrophage (TAM)-targeted systems have shown to deplete or repolarize macrophages to M1 state for anti-tumoral immune responses. Tumor-infiltrating T cell (TIT)-targeted strategies have provided the activation of effector T cells and suppression of regulatory T cells in tumor, overcoming the current hurdles of single regimen checkpoint inhibitors. Lastly, recent studies on dendritic cell-targeted mRNA vaccination are discussed and the future perspectives of nano-immunotherapeutic for next-generation of cancer immunotherapy is emphasized.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immune cells in cancer · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The biology and function of fibroblasts in cancer10.1038/nrc.2016.73 ↗
2. Tumor endothelial cells10.1101/cshperspect.a006536 ↗
3. Understanding the tumor immune microenvironment (TIME) for effective therapy
4. The role of myeloid cells in cancer therapies10.1038/nrc.2016.54 ↗
5. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis10.1038/bjc.2011.189 ↗
6. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis10.1016/S0140-6736(18)30533-6 ↗
7. IL-2: the first effective immunotherapy for human cancer10.4049/jimmunol.1490019 ↗
8. Checkpoint blocking antibodies in cancer immunotherapy10.1016/j.febslet.2013.10.015 ↗
9. CAR T cell immunotherapy for human cancer10.1126/science.aar6711 ↗
10. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
11. Immune-related adverse events associated with immune checkpoint blockade10.1056/NEJMra1703481 ↗
12. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade10.1038/s41591-018-0041-7 ↗
13. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells10.1038/s41591-018-0036-4 ↗
14. Delivering safer immunotherapies for cancer10.1016/j.addr.2017.05.011 ↗
15. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?10.1021/acs.bioconjchem.6b00437 ↗
16. Investigating the optimal size of anticancer nanomedicine10.1073/pnas.1411499111 ↗
17. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size10.1038/nnano.2011.166 ↗
18. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery10.1038/nnano.2015.342 ↗
19. Engineering nanoparticle strategies for effective cancer immunotherapy10.1016/j.biomaterials.2018.03.036 ↗
20. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation10.1155/2010/201026 ↗
21. Macrophages associated with tumors as potential targets and therapeutic intermediates10.2217/nnm.14.13 ↗
22. Movahedi · 2010 · 0008
23. Tumor-associated macrophages: from mechanisms to therapy10.1016/j.immuni.2014.06.010 ↗
24. Macrophage diversity enhances tumor progression and metastasis10.1016/j.cell.2010.03.014 ↗
25. Natural and induced T regulatory cells in cancer10.3389/fimmu.2013.00190 ↗
26. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis10.1016/j.cell.2006.01.007 ↗
27. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors10.1158/0008-5472.CAN-06-1823 ↗
28. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs10.1083/jcb.201301001 ↗
29. Microenvironmental regulation of tumor progression and metastasis10.1038/nm.3394 ↗
30. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth10.1371/journal.pone.0006562 ↗
31. Origins of tumor-associated macrophages and neutrophils10.1073/pnas.1113744109 ↗
32. The cellular and molecular origin of tumor-associated macrophages
33. DeNardo · 2011
34. CSF-1R inhibition alters macrophage polarization and blocks glioma progression10.1038/nm.3337 ↗
35. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses10.1158/0008-5472.CAN-12-2731 ↗
36. SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions10.1126/science.aaf1328 ↗
37. The nature of myeloid-derived suppressor cells in the tumor microenvironment10.1016/j.it.2016.01.004 ↗
38. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
39. Molecular and cellular insights into T cell exhaustion10.1038/nri3862 ↗
40. The pros and cons of dying tumour cells in adaptive immune responses10.1038/nri.2017.87 ↗
41. Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening
42. T-cell exhaustion in the tumor microenvironment10.1038/cddis.2015.162 ↗
43. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function10.1016/j.ccell.2014.10.018 ↗
44. TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients10.1172/JCI80445 ↗
45. Reversing T-cell dysfunction and exhaustion in cancer10.1158/1078-0432.CCR-15-1849 ↗
46. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors10.1084/jem.20140559 ↗
47. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics10.4049/jimmunol.1402669 ↗
48. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells
49. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting10.3390/vaccines4030028 ↗
50. Metabolic regulation of tregs in cancer: opportunities for immunotherapy10.1016/j.trecan.2017.06.005 ↗
51. Th17 cells in protection from tumor or promotion of tumor progression10.4172/2155-9899.1000431 ↗
52. The role and regulation of human Th17 cells in tumor immunity10.1016/j.ajpath.2012.08.041 ↗
53. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients10.1158/0008-5472.CAN-12-2583 ↗
54. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells10.1158/1078-0432.CCR-15-2205 ↗
55. Pillars article: induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997. 159: 4772–478010.1093/jimmunol/197.5.1547 ↗
56. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo10.1084/jem.194.6.769 ↗
57. Induction of interleukin 10–producing, nonproliferating Cd4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells10.1084/jem.192.9.1213 ↗
58. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer10.4049/jimmunol.1100274 ↗
59. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity10.1038/ncomms13720 ↗
60. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity10.1084/jem.20171440 ↗
61. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models10.1158/0008-5472.CAN-13-3723 ↗
62. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages10.1038/nature21409 ↗
63. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis10.1016/j.celrep.2016.04.084 ↗
64. Lipid-like materials for low-dose, in vivo gene silencing10.1073/pnas.0910603106 ↗
65. Therapeutic siRNA silencing in inflammatory monocytes in mice10.1038/nbt.1989 ↗
66. Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy10.1021/acs.molpharmaceut.7b00997 ↗
67. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer10.7150/thno.11546 ↗
68. Noninvasive imaging of CD206-positive M2 macrophages as an early biomarker for post-chemotherapy tumor relapse and lymph node metastasis10.7150/thno.20999 ↗
69. Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles10.1021/mp300434e ↗
70. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles10.1021/mp400216r ↗
71. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer10.1021/acs.molpharmaceut.5b00987 ↗
72. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells10.1016/j.biomaterials.2018.09.017 ↗
73. Reprogramming tumor-associated macrophages to reverse EGFRT790M resistance by dual-targeting codelivery of gefitinib/vorinostat10.1021/acs.nanolett.7b03756 ↗
74. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration10.1021/acs.nanolett.8b03568 ↗
75. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy10.1016/j.jconrel.2011.11.013 ↗
76. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy10.1016/j.biomaterials.2017.04.043 ↗
77. ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy10.1021/acs.biomac.8b00239 ↗
78. Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer10.1158/1078-0432.CCR-17-2587 ↗
79. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival10.1073/pnas.1312197110 ↗
80. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells10.1002/adfm.201501283 ↗
81. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages10.1021/acsnano.7b05465 ↗
82. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy10.1073/pnas.1522080113 ↗
83. Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy10.1021/acs.nanolett.7b01193 ↗
84. A formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines10.1038/srep46426 ↗
85. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy10.1038/s41551-018-0236-8 ↗
86. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle10.1126/scitranslmed.aac6522 ↗
87. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages10.1002/adhm.201601012 ↗
88. Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating MicroRNA-125b10.1021/acs.nanolett.8b00689 ↗
89. Phase ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors10.1158/1078-0432.CCR-17-1243 ↗
90. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy10.1182/blood-2017-07-741025 ↗
91. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
92. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells10.1016/j.biomaterials.2013.09.050 ↗
93. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro10.1016/j.bbrc.2011.06.164 ↗
94. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity10.1021/nn405520d ↗
95. Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth10.1021/acsnano.6b08152 ↗
96. A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy10.1002/adma.201706098 ↗
97. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy10.1021/acs.nanolett.8b01071 ↗
98. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation10.1016/j.jconrel.2016.01.044 ↗
99. dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis10.1038/ncomms9244 ↗
100. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis10.1038/s41467-017-02731-6 ↗